Literature DB >> 23037621

Victoria Symptom Validity Test performance in children and adolescents with neurological disorders.

Brian L Brooks1.   

Abstract

It is becoming increasingly more important to study, use, and promote the utility of measures that are designed to detect non-compliance with testing (i.e., poor effort, symptom non-validity, response bias) as part of neuropsychological assessments with children and adolescents. Several measures have evidence for use in pediatrics, but there is a paucity of published support for the Victoria Symptom Validity Test (VSVT) in this population. The purpose of this study was to examine the performance on the VSVT in a sample of pediatric patients with known neurological disorders. The sample consisted of 100 consecutively referred children and adolescents between the ages of 6 and 19 years (mean = 14.0, SD = 3.1) with various neurological diagnoses. On the VSVT total items, 95% of the sample had performance in the "valid" range, with 5% being deemed "questionable" and 0% deemed "invalid". On easy items, 97% were "valid", 2% were "questionable", and 1% was "invalid." For difficult items, 84% were "valid," 16% were "questionable," and 0% was "invalid." For those patients given two effort measures (i.e., VSVT and Test of Memory Malingering; n = 65), none was identified as having poor test-taking compliance on both measures. VSVT scores were significantly correlated with age, intelligence, processing speed, and functional ratings of daily abilities (attention, executive functioning, and adaptive functioning), but not objective performance on the measure of sustained attention, verbal memory, or visual memory. The VSVT has potential to be used in neuropsychological assessments with pediatric patients.

Entities:  

Mesh:

Year:  2012        PMID: 23037621     DOI: 10.1093/arclin/acs087

Source DB:  PubMed          Journal:  Arch Clin Neuropsychol        ISSN: 0887-6177            Impact factor:   2.813


  1 in total

Review 1.  Victoria Symptom Validity Test: A Systematic Review and Cross-Validation Study.

Authors:  Zachary J Resch; Troy A Webber; Matthew T Bernstein; Tasha Rhoads; Gabriel P Ovsiew; Jason R Soble
Journal:  Neuropsychol Rev       Date:  2021-01-12       Impact factor: 7.444

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.